TW202342102A - 治療兒科病症之方法 - Google Patents

治療兒科病症之方法 Download PDF

Info

Publication number
TW202342102A
TW202342102A TW112126603A TW112126603A TW202342102A TW 202342102 A TW202342102 A TW 202342102A TW 112126603 A TW112126603 A TW 112126603A TW 112126603 A TW112126603 A TW 112126603A TW 202342102 A TW202342102 A TW 202342102A
Authority
TW
Taiwan
Prior art keywords
antibody
dose
weeks
seq
response
Prior art date
Application number
TW112126603A
Other languages
English (en)
Chinese (zh)
Inventor
瑪利亞 羅莎莉歐
麥可 A 斯特茲林
威廉 R 崔姆
Original Assignee
美商千禧製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商千禧製藥公司 filed Critical 美商千禧製藥公司
Publication of TW202342102A publication Critical patent/TW202342102A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW112126603A 2017-04-28 2018-04-27 治療兒科病症之方法 TW202342102A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762492031P 2017-04-28 2017-04-28
US62/492,031 2017-04-28

Publications (1)

Publication Number Publication Date
TW202342102A true TW202342102A (zh) 2023-11-01

Family

ID=62455814

Family Applications (2)

Application Number Title Priority Date Filing Date
TW112126603A TW202342102A (zh) 2017-04-28 2018-04-27 治療兒科病症之方法
TW107114371A TWI811216B (zh) 2017-04-28 2018-04-27 治療兒科病症之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW107114371A TWI811216B (zh) 2017-04-28 2018-04-27 治療兒科病症之方法

Country Status (13)

Country Link
US (1) US20200179486A1 (cg-RX-API-DMAC10.html)
EP (1) EP3615071A2 (cg-RX-API-DMAC10.html)
JP (3) JP2020517671A (cg-RX-API-DMAC10.html)
KR (2) KR20190141148A (cg-RX-API-DMAC10.html)
CN (1) CN110612120A (cg-RX-API-DMAC10.html)
AR (1) AR111491A1 (cg-RX-API-DMAC10.html)
AU (2) AU2018256840A1 (cg-RX-API-DMAC10.html)
BR (1) BR112019022268A2 (cg-RX-API-DMAC10.html)
CA (1) CA3061320A1 (cg-RX-API-DMAC10.html)
IL (1) IL270201B2 (cg-RX-API-DMAC10.html)
MX (4) MX2019012749A (cg-RX-API-DMAC10.html)
TW (2) TW202342102A (cg-RX-API-DMAC10.html)
WO (1) WO2018200818A2 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3224280A1 (en) 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
US20230096620A1 (en) * 2019-04-17 2023-03-30 Millennium Pharmaceuticals, Inc. Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
CN115515435A (zh) * 2020-02-11 2022-12-23 沃尔夫森医疗中心 有效治疗溃疡性结肠炎的方法
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use
WO2025177055A1 (en) * 2024-02-20 2025-08-28 Takeda Pharmaceutical Company Limited Combination therapy for treating inflammatory bowel disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
ATE366809T1 (de) 1995-02-10 2007-08-15 Millennium Pharm Inc Addressine der schleimhaut und der blutgefässe und ihre verwendung
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
AU2003248549B2 (en) 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
AU2003298661B2 (en) 2002-11-18 2007-05-10 Chemocentryx, Inc. Aryl sulfonamides
ES2377979T3 (es) 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
EP1948691A1 (en) 2005-11-17 2008-07-30 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN
PE20120497A1 (es) 2009-03-20 2012-05-14 Amgen Inc Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
EP3978530A1 (en) * 2015-02-26 2022-04-06 F. Hoffmann-La Roche AG Integrin beta7 antagonists and methods of treating crohn's disease
MA43755A (fr) * 2016-03-14 2018-11-28 Millennium Pharm Inc Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte

Also Published As

Publication number Publication date
MX2024012972A (es) 2024-11-08
KR20190141148A (ko) 2019-12-23
RU2019138312A3 (cg-RX-API-DMAC10.html) 2022-02-03
KR20250134146A (ko) 2025-09-09
IL270201B1 (en) 2026-01-01
WO2018200818A2 (en) 2018-11-01
JP2023113655A (ja) 2023-08-16
AU2018256840A1 (en) 2019-11-07
JP2026120554A (ja) 2026-07-22
WO2018200818A3 (en) 2018-12-06
IL270201B2 (en) 2026-05-01
MX2024003906A (es) 2024-04-23
EP3615071A2 (en) 2020-03-04
TW201842932A (zh) 2018-12-16
BR112019022268A2 (pt) 2020-05-19
IL270201A (cg-RX-API-DMAC10.html) 2019-12-31
MX2019012749A (es) 2020-02-03
AR111491A1 (es) 2019-07-17
US20200179486A1 (en) 2020-06-11
RU2019138312A (ru) 2021-05-28
TWI811216B (zh) 2023-08-11
WO2018200818A9 (en) 2019-01-17
AU2025202525A1 (en) 2025-05-01
CA3061320A1 (en) 2018-11-01
CN110612120A (zh) 2019-12-24
JP2020517671A (ja) 2020-06-18
MX2024003905A (es) 2024-04-23

Similar Documents

Publication Publication Date Title
US20240368263A1 (en) Optimized anti-tl1a antibodies
TWI811216B (zh) 治療兒科病症之方法
JP6297088B2 (ja) Ｐｃｓｋ９アンタゴニスト
JP6668461B2 (ja) 炎症性疾患の処置法
US11440965B2 (en) Anti-OX40 antibody
KR20160105918A (ko) 베타7 인테그린 길항제를 투여하는 방법
JP7512433B2 (ja) 抗ｐｄ－１抗体
JP7202893B2 (ja) 炎症性腸疾患を治療する方法
JP2019528285A (ja) 抗ｎｋｇ２ｄ抗体を用いたクローン病の治療方法
JP2019536756A (ja) Ｉｌ−２３ａ抗体を用いて疾患を処置する方法
CN114630680B (zh) 用于治疗乙型肝炎病毒感染的抗体组合物和方法
CN119768431A (zh) Igf1r抗体
RU2778567C2 (ru) Способ лечения педиатрических расстройств/заболеваний
WO2021236509A1 (en) Anti-sars-cov-2 antibodies and uses thereof
HK40123789A (en) Optimized anti-tl1a antibodies
HK40042163B (en) Optimized anti-tl1a antibodies
HK40038976A (en) Isolated antibody or antigen binding fragment thereof and use of same in tumor treatment